Aumilto Silva, Medical Oncologist, Senior Research Investigator Brazilian Clinical Research Institute, shared. a post on X:
“Do PARP inhibitors perform as well in the real world as in trials? PARP inhibitors in real-world HER2- advanced breast cancer (PRAEGNANT registry).
In 152 patients treated with olaparib/talazoparib:
- Median rwPFS: 6.2 mo
- Median rwOS: 17.1 mo
Outcomes varied by line of therapy, HR status, and agent. HR+ patients had longer PFS vs TNBC (7.3 vs 4.5 mo). Earlier-line use showed better outcomes. Despite frequent later-line use, results were broadly consistent with pivotal trials → supports effectiveness in routine practice. Real-world data reinforce PARP inhibitors as a valid standard in gBRCA-mutated HER2- ABC.”
Title: PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry
Authors: Manuel Hörner, Andreas Hartkopf, Nelson John, Philipp Ziegler, Lothar Häberle, Sabrina Uhrig, Chloë Goossens, Niklas Amann, Jan-Philipp Cieslik, Lara M. Tretschock, Dominik Dannehl, Thomas M. Deutsch, Moritz Dimpfl, Max Ehlert, Kathleen Eichstädt, Alexander Englisch, Melitta B. Köpke, Annika Krückel, Theresa Link, Annika Müller, Kristin Reinhardt, Jonas Roth, Henning Schäffler, Lea Sych, Nikolas Tauber, Christian M. Tegeler, Catharina Wichmann, Maggie Banys-Paluchowski, Henriette Princk, Achim Rody, Sara Y. Brucker, Nina Ditsch, Johannes Ettl, Tanja Fehm, Carolin C. Hack, Peyman Hadji, Alexander Hein, Wolfgang W. Janni, Hans-Christian Kolberg, Diana Lüftner, Michael P. Lux, Volkmar Müller, Florin-Andrei Taran, Hans Tesch,
Diethelm Wallwiener, Frederik Marmé, Stephan Seitz, Erik Belleville, Laura L. Michel, Markus Wallwiener, Peter A. Fasching, Andreas Schneeweiss, Christian Maurer
Read the full article here.
Other articls about Aumilto Silva on OncoDaily.
